Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

It feels like the Splinter Cell remake has been on its way for a while now, which isn't helped by the fact it's been over three years since we heard anything official about the game. From what we ...

McDermott first revealed in 2021 that he had squamous cell carcinoma "several times." He added that he also has had basal cell cancer. According to the American Cancer Society, basal cell and ...

Basal cell carcinoma (BCC) is an epithelial tumour of the skin. It seldom metastasizes, but has the potential for local invasion and destruction. It usually occurs as one or several small pearly ...

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for 80 to 85% of all cases of lung cancer. There are different stages of NSCLC, ranging from 0 to 4; ...

Lung cancer survival without treatment is shorter than survival with treatment. People with untreated non-small cell lung cancer—the most common type—typically live between five and 12 months after ...

In a significant step forward for India’s cancer treatment, Immuneel Therapeutics, a leading cell and gene therapy statrtup backed by entrepreneur Kiran Mazumdar-Shaw, has unveiled Qartemi, the ...

Iran has unveiled an underground naval base capable of taking on "enemies big and small". Footage broadcast on state TV shows a large number of speedboats lined up in what appears to be an ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Ubisoft is apparently endeavoring to work with Tencent to bring forth new ventures, one of which is the rumored Splinter Cell Remake. During an address, Guillemot confirmed numerous titles were in ...